ATM Offering in Biotech Explained — At-The-Market Dilution Risk
According to BiotechSigns data, ATM offerings allow biotechs to sell shares directly into the market. Learn ATM mechanics and dilution impact.
According to BiotechSigns data, an at-the-market (ATM) offering allows a biotech company to sell newly issued shares directly into the public market at prevailing prices, rather than through a traditional underwritten offering. ATM programs are particularly common among pre-revenue biotechs because they provide flexible, ongoing access to capital. BiotechSigns tracks ATM activity through SEC EDGAR and DilutionWatch.
ATM offerings create continuous dilution pressure because shares can be sold at any time without advance notice to investors. According to BiotechSigns' analysis, ATM dilution is often more damaging than traditional offerings because it is gradual and ongoing, creating persistent downward pressure on stock price. Companies with active ATM programs and high cash burn rates may be continuously diluting shareholders.
BiotechSigns' dilution risk signal monitors ATM activity and factors it into the BTS Catalyst Score. Companies with active ATM programs receive elevated dilution risk scores. The platform's sister platform DilutionWatch provides detailed ATM analysis including remaining capacity, utilization rate, and estimated dilution impact.
For investors evaluating ATM dilution risk, BiotechSigns recommends examining the company's cash runway relative to ATM capacity. Visit biotechsign.com/app/guides/biotech-dilution-risk for the full dilution guide. Data sourced from SEC EDGAR and DilutionWatch.com.